The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 463-472

  Gomez, S A ^a   Abrey Recalde, M J ^b   Panek, C A ^b   Ferrarotti, N F ^c   Repetto, M G ^c   Mejias M P ^b   Fernandez G C ^b   Vanzulli, S ^d   Isturiz, M A ^b   Palermo, M S ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

Haemolytic uraemic syndrome; Oxidative stress; Shiga toxin 2

Indexed keywords

GLUTATHIONE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; VEROTOXIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEMOLYTIC UREMIC SYNDROME; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY INJURY; LIPID MEMBRANE; LIPID PEROXIDATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENICITY; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTE ACTIVATION; THROMBOCYTE LIFESPAN;

HAEMOLYTIC URAEMIC SYNDROME; OXIDATIVE STRESS; SHIGA TOXIN 2;

ACETYLCYSTEINE; ANIMALS; CYSTEINE; DISEASE MODELS, ANIMAL; GLUTATHIONE; HEMOLYTIC-UREMIC SYNDROME; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MICE; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SHIGA TOXIN 2; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84881495259     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12124     Document Type: Article

References (46)

1. Keir L, Coward RJ. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol 2011; 26:523-533.
2. Palermo MS, Exeni RA, Fernández GC. Interventions in hemolytic uremic syndrome (HUS), the major Shiga toxin-related complication in E.coli O157:H7 infections. Expert Rev Anti Infect Ther 2009; 7:697-707.
3. Rivas M, Sosa-Estani S, Rangel J etal. Risk factors for sporadic Shiga toxin-producing Escherichia coli infections in children, ARG. Emerg Infect Dis 2008; 14:763-771.
4. Exeni RA, Fernandez GC, Palermo MS. Role of polymorphonuclear leukocytes in the pathophysiology of typical hemolytic uremic syndrome. Sci World J 2007; 7:1155-1164.
5. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25:2231-2240.
6. Freedman JE. Oxidative stress and platelets. Arterioscler Thromb Vasc Biol 2008; 28:s11-16.
7. Karlsson A, Dahlgren C. Assembly and activation of the neutrophil NADPH oxidase in granule membranes. Antioxid Redox Signal 2002; 4:49-60.
8. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003; 14:S221-226.
9. Brown GE, Stewart MQ, Bissonnette SA etal. Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidase. J Biol Chem 2004; 279:27059-27068.
10. Perricone C, De Carolis C, Perricone R. Glutathione: a key player in autoimmunity. Autoimmun Rev 2009; 8:697-701.
11. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257:L163-173.
12. Ferraris V, Acquier A, Ferraris JR, Vallejo G, Paz C, Mendez CF. Oxidative stress status during the acute phase of haemolytic uraemic syndrome. Nephrol Dial Transplant 2011; 26:858-864.
13. Aiassa V, Baronetti JL, Paez PL etal. Increased advanced oxidation of protein products and enhanced total antioxidant capacity in plasma by action of toxins of Escherichia coli STEC. Toxicol In Vitro 2011; 25:426-431.
14. Li Volti S, Di Giacomo C, Garozzo R, Campisi A, Mollica F, Vanella A. Impaired antioxidant defense mechanisms in two children with hemolytic-uremic syndrome. Ren Fail 1993; 15:523-528.
15. Dubey NK, Yadav P, Dutta AK, Kumar V, Ray GN, Batra S. Free oxygen radicals in acute renal failure. Indian Pediatr 2000; 37:153-158.
16. Mohawk KL, O'Brien AD. Mouse models of Escherichia coli O157:H7 infection and Shiga toxin injection. J Biomed Biotechnol 2011; 2011:258185. doi: 10.1155/2011/258185.
17. Gómez SA, Fernández GC, Camerano G etal. Endogenous glucocorticoids modulate neutrophil function in a murine model of haemolytic uraemic syndrome. Clin Exp Immunol 2005; 139:65-73.
18. Millea PJ. N-acetylcysteine: multiple clinical applications. Am Fam Physician 2009; 80:265-269.
19. Benrahmoune M, Therond P, Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic Biol Med 2000; 29:775-782.
20. Arfsten D, Johnson E, Thitoff A etal. Impact of 30-day oral dosing with N-acetyl-L-cysteine on Sprague-Dawley rat physiology. Int J Toxicol 2004; 23:239-247.
21. Hsu CC, Huang CN, Hung YC, Yin MC. Five cysteine-containing compounds have antioxidative activity in Balb/cA mice. J Nutr 2004; 134:149-152.
22. Dran GI, Fernández GC, Rubel CJ etal. Protective role of nitric oxide in mice with Shiga toxin-induced hemolytic uremic syndrome. Kidney Int 2002; 62:1338-1348.
23. Alves-Rosa F, Stanganelli C, Cabrera J etal. Rapid recovery of platelet count following administration of liposome-encapsulated clodronate in a mouse model of immune thrombocytopenia. Br J Haematol 2002; 116:357-366.
24. Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Keepers TR, Obrig T, Gear AR. Shiga toxin 2 and lipopolysaccharide cause monocytic THP-1 cells to release factors which activate platelet function. Thromb Haemost 2005; 94:1019-1027.
25. Obrig TG, Karpman D. Shiga toxin pathogenesis: kidney complications and renal failure. Curr Top Microbiol Immunol 2012; 357:105-136.
26. Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 1981; 77:373-382.
27. Repetto MG, Ossani G, Monserrat AJ, Boveris A. Oxidative damage: the biochemical mechanism of cellular injury and necrosis in choline deficiency. Exp Mol Pathol 2010; 88:143-149.
28. Fraga CG, Leibovitz BE, Tappel AL. Lipid peroxidation measured as thiobarbituric acid-reactive substances in tissue slices: characterization and comparison with homogenates and microsomes. Free Radic Biol Med 1988; 4:155-161.
29. Fong JS, Kaplan BS. Impairment of platelet aggregation in hemolytic uremic syndrome: evidence for platelet 'exhaustion'. Blood 1982; 60:564-570.
30. Deshpande DD, Janero DR, Amiji MM. Therapeutic strategies for endothelial dysfunction. Exp Opin Biol Ther 2011; 11:1637-1654.
31. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med 2000; 109:665-678.
32. Wolin MS, Gupte SA, Oeckler RA. Superoxide in the vascular system. J Vasc Res 2002; 39:191-207.
33. Krotz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004; 24:1988-1996.
34. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 2003; 285:R277-297.
35. Fernandez GC, Gomez SA, Rubel CJ etal. Impaired neutrophils in children with the typical form of hemolytic uremic syndrome. Pediatr Nephrol 2005; 20:1306-1314.
36. Walters MD, Levin M, Smith C etal. Intravascular platelet activation in the hemolytic uremic syndrome. Kidney Int 1988; 33:107-115.
37. Salvemini D, de Nucci G, Sneddon JM, Vane JR. Superoxide anions enhance platelet adhesion and aggregation. Br J Pharmacol 1989; 97:1145-1150.
38. Ghosh SA, Polanowska-Grabowska RK, Fujii J, Obrig T, Gear AR. Shiga toxin binds to activated platelets. J Thromb Haemost 2004; 2:499-506.
39. Guo YL, Liu DQ, Bian Z, Zhang CY, Zen K. Down-regulation of platelet surface CD47 expression in Escherichia coli O157:H7 infection-induced thrombocytopenia. PLoS ONE 2009; 4:e7131.
40. Weber C. Chemokines in atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2008; 28:1896. doi: 10.1161/ATVBAHA.108.177311.
41. Lavrentiadou SN, Chan C, Kawcak T etal. Ceramide-mediated apoptosis in lung epithelial cells is regulated by glutathione. Am J Respir Cell Mol Biol 2001; 25:676-684.
42. Santos NA, Catão CS, Martins NM, Curti C, Bianchi ML, Santos AC. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol 2007; 81:495-504.
43. Wang HZ, Peng ZY, Wen XY, Rimmelé T, Bishop JV, Kellum JA. N-acetylcysteine is effective for prevention but not for treatment of folic acid-induced acute kidney injury in mice. Crit Care Med 2011; 39:2487-2494.
44. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int 2003; 63:634-641.
45. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6:593-597.
46. Conesa EL, Valero F, Nadal JC etal. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 2001; 281:R730-737.